CHRISTIANAH EGIEFAMEH: Open Payments
NPI 1790328268 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,765 in 61 payments from 12 companies in 2025. Trend: 2023 $245 · 2024 $512 · 2025 $1,765
Food & beverage: $1,754Education: $11
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 9 | $487 |
| Neurocrine BioSciences, Inc. | 15 | $345 |
| Janssen Pharmaceuticals, Inc | 7 | $241 |
| ABBVIE INC. | 13 | $232 |
| Alkermes, Inc. | 4 | $171 |
| Otsuka America Pharmaceutical, Inc. | 4 | $105 |
| Lundbeck LLC | 3 | $73 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: COBENFY, INGREZZA, VRAYLAR, INVEGA SUSTENNA, LYBALVI, ABILIFY MAINTENA, ABILIFY ASIMTUFII, Auvelity.
Industry payments across MD — which companies pay providers there.
